AnaptysBio reports Q1 net loss of $44.3M; initiates Phase 2b for ANB032 in atopic dermatitis

ANAPTYSBIO, INC

2023-Q1 EPS reported -$1.58 revenue$1,374,000

Net loss of $44.3M ($1.58 per share) vs $36.3M loss in Q1 2022; R&D expenses rose to $35.0M.
Cash and investments totaled $526.1M; reiterated cash runway through year-end 2026.
Completed $50M stock repurchase program authorized in January 2023.
Initiated global Phase 2b trial for ANB032 (BTLA agonist) in moderate-to-severe atopic dermatitis; top-line data expected by year-end 2024.
Plans to start Phase 2b trial for rosnilimab in rheumatoid arthritis in Q3 2023 and second Phase 2 trial by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ANAPTYSBIO, INC reported financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.